LANXESS Aktiengesellschaft

BATS-CHIXE:LXSD Stock Report

Market Cap: €2.0b

LANXESS Valuation

Is LXSD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of LXSD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: LXSD (€23.15) is trading below our estimate of fair value (€51.81)

Significantly Below Fair Value: LXSD is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for LXSD?

Key metric: As LXSD is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for LXSD. This is calculated by dividing LXSD's market cap by their current revenue.
What is LXSD's PS Ratio?
PS Ratio0.3x
Sales€6.32b
Market Cap€2.05b

Price to Sales Ratio vs Peers

How does LXSD's PS Ratio compare to its peers?

The above table shows the PS ratio for LXSD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average1.6x
JMAT Johnson Matthey
0.2x-48.2%UK£2.3b
ELM Elementis
1.4x3.4%UK£781.6m
VCT Victrex
2.7x5.8%UK£756.5m
CEY Centamin
2.3x5.7%UK£1.7b
LXSD LANXESS
0.3x2.8%€2.0b

Price-To-Sales vs Peers: LXSD is good value based on its Price-To-Sales Ratio (0.3x) compared to the peer average (1.6x).


Price to Sales Ratio vs Industry

How does LXSD's PS Ratio compare vs other companies in the GB Chemicals Industry?

6 CompaniesPrice / SalesEstimated GrowthMarket Cap
JMAT Johnson Matthey
0.2x-48.2%US$2.88b
SYNT Synthomer
0.1x5.0%US$344.50m
CAR Carclo
0.2x7.0%US$30.55m
HEIQ HeiQ
0.2xn/aUS$9.61m
No. of Companies6PS01.22.43.64.86+
6 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: LXSD is good value based on its Price-To-Sales Ratio (0.3x) compared to the UK Chemicals industry average (1.3x).


Price to Sales Ratio vs Fair Ratio

What is LXSD's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

LXSD PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.3x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate LXSD's Price-To-Sales Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst LXSD forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€23.15
€28.84
+24.6%
19.5%€38.00€20.00n/a16
Nov ’25€26.57
€30.47
+14.7%
20.2%€42.00€21.00n/a17
Oct ’25€28.41
€29.03
+2.2%
19.9%€42.00€21.00n/a18
Sep ’25n/a
€28.08
0%
20.0%€42.00€21.00n/a18
Aug ’25€24.20
€28.44
+17.6%
19.2%€42.00€21.00n/a18
Jul ’25n/a
€28.34
0%
18.5%€42.00€21.00n/a19
Jun ’25n/a
€28.71
0%
18.0%€42.00€21.00n/a19
May ’25n/a
€28.15
0%
17.4%€42.00€21.00n/a19
Apr ’25n/a
€28.12
0%
18.6%€42.00€21.00n/a19
Mar ’25€23.99
€28.67
+19.5%
18.9%€42.00€21.00n/a18
Feb ’25n/a
€28.67
0%
18.9%€42.00€21.00n/a18
Jan ’25n/a
€29.08
0%
20.1%€42.00€21.00n/a18
Dec ’24n/a
€31.82
0%
31.6%€65.00€21.00n/a19
Nov ’24€20.83
€33.29
+59.8%
29.4%€65.00€24.00€26.5719
Oct ’24€24.04
€36.82
+53.2%
29.1%€65.00€25.00€28.4119
Sep ’24n/a
€38.85
0%
25.9%€65.00€28.00n/a20
Aug ’24n/a
€40.77
0%
27.8%€65.00€23.30€24.2020
Jul ’24€27.69
€42.13
+52.2%
26.2%€65.00€23.30n/a21
Jun ’24€33.44
€49.88
+49.2%
18.9%€69.00€35.00n/a21
May ’24€36.75
€50.81
+38.3%
18.3%€69.00€35.00n/a21
Apr ’24€37.44
€50.62
+35.2%
17.9%€69.00€35.00n/a21
Mar ’24€43.80
€52.29
+19.4%
14.8%€69.00€40.00€23.9921
Feb ’24€45.64
€52.24
+14.5%
14.7%€69.00€40.00n/a21
Jan ’24n/a
€50.50
0%
17.3%€69.00€37.50n/a21
Dec ’23€38.49
€50.93
+32.3%
17.3%€72.00€37.50n/a21
Nov ’23€34.46
€50.55
+46.7%
21.1%€72.00€31.50€20.8321

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies